Formulation and Optimization of Orodispersible Tablet of Loratadine Using Box Behnken Design

  • Aliasgar Kundawala
  • Pratik Patel
  • Khushbu Chauhan
  • Anjali Desai
  • Dhwani Kapadia

Abstract

In present study Orodispersible tablets (ORDT) of Loratadine were prepared and optimized. Solid dispersion of Loratadine- β cyclodextrin complex were prepared and used in preparation of Orodispersible tablets. Various super-disintegrating agent like Cross carmellose sodium, Cross povidone and Kyron T-314 were employed for faster disintegrating effect. The 24 factorial and Box-Behnken design were utilized to optimize the tablet formulation. The Orodispersible tablet of Loratadine was optimized by Box Behnken Design, where concentrations Kyron T-314, CRP and Pearlitol SD200 were employed and its effect on Disintegration time (DT), Wetting time (WT) and % drug release at 20 min (Q20) was evaluated. Precompression parameters like angle of repose, bulk density, % compressibility, Hausner’s ratio was studies. The different batches of Orodispersable tablets were prepared and evaluated for disintegration time, friability, wetting time and drug release studies. Different batches prepared showed disintegration time in the range of 23 ± 2.52 to 59 ± 2.64, wetting time in between 27± 0.57 to 66.3 ± 3.4, drug release (Q 20) in between 86.1 ± 0.6 to 96.7 ± 0.4 in 20 min., friability less than 1 % and hardness 3.4 to 4.2 Kg/cm2. The optimized formula when compared with marketed product it showed faster disintegration time and rapid drug dissolution in phosphate buffer 6.8. The solid dispersion of Loratadine not only helped improve in solubility but may also help in taste masking.


Keywords: Orodispersible tablets, Loratadine, β cyclodextrin Solid dispersion

Downloads

Download data is not yet available.
Statistics
22 Views | 58 Downloads
How to Cite
Kundawala, A., Patel, P., Chauhan, K., Desai, A., & Kapadia, D. (2019). Formulation and Optimization of Orodispersible Tablet of Loratadine Using Box Behnken Design. Journal of Drug Delivery and Therapeutics, 9(4-A), 86-94. https://doi.org/10.22270/jddt.v9i4-A.3402